Improve Medical Instruments Co., Ltd. (300030.SZ)
CNY 6.6
(-2.37%)
CNY 6.6
(-2.37%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 644.62 Million | 710.76 Million | 799.83 Million | 919.22 Million | 575.06 Million | 549.96 Million |
| Cost of Revenue | 410.9 Million | 446.34 Million | 473.32 Million | 488.94 Million | 325.49 Million | 326.39 Million |
| Gross Profit | 233.71 Million | 264.41 Million | 326.51 Million | 430.27 Million | 249.57 Million | 223.56 Million |
| Operating Expenses | 301.13 Million | 280.56 Million | 264.01 Million | 258.63 Million | 202.58 Million | 211.47 Million |
| Selling, General and Administrative Expenses | 160.97 Million | 164.88 Million | 147.43 Million | 166.97 Million | 131.74 Million | 139.9 Million |
| Research and Development Expenses | 37.52 Million | 43.66 Million | 42.32 Million | 46.56 Million | 23.5 Million | 25.52 Million |
| Other Expenses | 76.03 Million | 72.01 Million | 74.25 Million | 45.09 Million | 47.32 Million | -172.08 Thousand |
| Cost and Expenses | 685.43 Million | 726.91 Million | 737.33 Million | 747.58 Million | 528.07 Million | 537.86 Million |
| Operating Income | -40.81 Million | -16.14 Million | 82.92 Million | 255.41 Million | 69.39 Million | -144.31 Million |
| Interest Expense | 16.56 Million | 19.69 Million | 25.44 Million | 24.68 Million | 29.46 Million | 25.95 Million |
| Income Tax Expense | 17.15 Million | -21 Million | 4.07 Million | 1.76 Million | 10.86 Million | -3.49 Million |
| Earnings before Tax | -43.06 Million | -214.29 Million | 23.84 Million | 165.08 Million | 37 Million | -144.49 Million |
| Net Income | -63.2 Million | -193.29 Million | 18.56 Million | 162.51 Million | 26.02 Million | -136.8 Million |
| Earnings Per Share Basic | -0.20 | -0.63 | 0.06 | 0.53 | 0.08 | -0.44 |
| Earnings Per Share Diluted | -0.20 | -0.63 | 0.06 | 0.53 | 0.08 | -0.44 |
| Weighted Average Shares Outstanding | 316.01 Million | 309.18 Million | 309.18 Million | 308.79 Million | 308.79 Million | 308.79 Million |
| Weighted Average Shares Outstanding (Diluted) | 316.01 Million | 309.18 Million | 309.18 Million | 308.79 Million | 308.79 Million | 310.91 Million |
| Gross Margin | 0.36 | 0.37 | 0.41 | 0.47 | 0.43 | 0.41 |
| EBIT Margin | 0.03 | -0.03 | 0.17 | 0.32 | 0.18 | 0.09 |
| Profit Margin | -0.10 | -0.27 | 0.02 | 0.18 | 0.05 | -0.25 |
| EBITDA | 17.73 Million | -19.68 Million | 102.59 Million | 227.25 Million | 99.32 Million | -71.29 Million |
| Earnings Before Tax Margin | -0.06 | -0.02 | 0.10 | 0.28 | 0.12 | -0.26 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 128.3 Million | 150.32 Million | 141.15 Million | 644.62 Million | 172.22 Million | 152.63 Million |
| Cost of Revenue | 76.92 Million | 95.45 Million | 85.04 Million | 384.3 Million | 101.14 Million | 89.33 Million |
| Gross Profit | 51.38 Million | 54.87 Million | 56.1 Million | 260.31 Million | 71.07 Million | 63.29 Million |
| Operating Expenses | 45.08 Million | 51.04 Million | 47.57 Million | 263.99 Million | 85.77 Million | 62.65 Million |
| Selling, General and Administrative Expenses | 87.91 Million | 44.34 Million | 39.87 Million | - | 9.18 Million | 84.89 Million |
| Research and Development Expenses | 9.26 Million | 6.7 Million | 6.6 Million | - | 10.85 Million | 8.67 Million |
| Other Expenses | -52.09 Million | 6010.00 | -221.89 Thousand | -2.24 Million | -2.02 Million | -191.9 Thousand |
| Cost and Expenses | 122 Million | 146.49 Million | 132.62 Million | 648.3 Million | 186.92 Million | 151.99 Million |
| Operating Income | -38.06 Million | 3.82 Million | -1.39 Million | -40.81 Million | -48.85 Million | -5.16 Million |
| Interest Expense | 2.37 Million | 4.84 Million | 2.07 Million | 16.56 Million | 5.41 Million | 3.31 Million |
| Income Tax Expense | 1.92 Million | 96.3 Thousand | 1.27 Million | 17.15 Million | 14.89 Million | 650.33 Thousand |
| Earnings before Tax | -38.2 Million | 4.49 Million | -1.61 Million | -43.06 Million | -50.87 Million | -5.35 Million |
| Net Income | -37.24 Million | -2.08 Million | -3.19 Million | -63.2 Million | -66.38 Million | -7.27 Million |
| Earnings Per Share Basic | -0.12 | -0.01 | -0.01 | - | -0.21 | -0.02 |
| Earnings Per Share Diluted | -0.12 | -0.01 | -0.01 | - | -0.21 | -0.02 |
| Weighted Average Shares Outstanding | 309.18 Million | 309.18 Million | 319.08 Million | 316.01 Million | 317.55 Million | 309.18 Million |
| Weighted Average Shares Outstanding (Diluted) | 309.18 Million | 309.18 Million | 319.08 Million | 316.01 Million | 317.55 Million | 309.18 Million |
| Gross Margin | 0.40 | 0.37 | 0.40 | 0.40 | 0.41 | 0.41 |
| EBIT Margin | -0.28 | 0.10 | -0.00 | - | -0.11 | -0.02 |
| Profit Margin | -0.29 | -0.01 | -0.02 | -0.10 | -0.39 | -0.05 |
| EBITDA | -35.82 Million | 14.33 Million | -152.65 Thousand | - | -18.8 Million | -2.75 Million |
| Earnings Before Tax Margin | -0.30 | 0.03 | -0.01 | -0.06 | -0.28 | -0.03 |
300171
CMCXF
300732
RGL
FAGI
AUROLAB